Laurus Labs share news, announcements and annual reports
NSE: LAURUSLABSBSE: 540222Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 28 Oct 2026. Previous close ₹2,142.00.
28 Oct: open ₹2,142.00, high ₹2,198.80, low ₹2,131.70
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and dividend. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,17,891 Cr171st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 107.82
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 22.24
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.09%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 22.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.44
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 22,00,73141.9% delivered
Laurus Labs share news and announcements
573 announcements, routine notices left out, newest first. Page 2 of 12.
Jan 2026
23 Jan · Results
23 Jan · Options to purchase securities
12 Jan · Legal
Exchange has sought clarification from Laurus Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.9 Jan · Analysts
9 Jan · Board meeting
Dec 2025
23 Dec · General Updates
23 Dec · General Updates
12 Dec · Analysts
2 Dec · Disclosure
Nov 2025
19 Nov · Analysts
12 Nov · Analysts
Oct 2025
23 Oct · Business
23 Oct · Corporate action
23 Oct · Results
9 Oct · Analysts
Sep 2025
9 Sep · Analysts
Aug 2025
25 Aug · Analysts
21 Aug · Business
Jul 2025
27 Jul · General Updates
25 Jul · General Updates
25 Jul · Results
9 Jul · Analysts
9 Jul · Board meeting
1 Jul · Rating
Jun 2025
26 Jun · Meeting
26 Jun · General Updates
12 Jun · Analysts
9 Jun · Disclosure
5 Jun · General Updates
3 Jun · Updates
3 Jun · Meeting
May 2025
30 May · Disclosure
22 May · Analysts
Apr 2025
24 Apr · Results
24 Apr · Business
24 Apr · Corporate action
15 Apr
10 Apr · Analysts
Mar 2025
28 Mar · General Updates
28 Mar · General Updates
28 Mar · General Updates